录芝复方剂对K562白血病细胞增殖,分化的影响

用细胞培养、细胞形态学及联苯胺染色法观察中药灵芝复方对Ｋ５６２白血病细胞的增殖抑制及分化诱导作用。结果显示：灵芝复方在一定浓度范围内对正常人骨髓ＣＦＵ－ＭＧ生长有促进作用（Ｐ〈０．０５），而对白血病细胞系Ｋ５６２细胞才殖表现出剂量和时间依赖性抑制（Ｐ〈０．０５）；在诱导分化剂量下，灵芝复方可促进Ｋ５６２细胞向红系分化。可见，灵芝复方有望成为一种抗白血病中药。

Effects of Ganoderma lucidum (Leyss ex Fr) Karst compound on the proliferation and differentiation of K562 leukemic cells]

A series of experiments including cell culture and benzidine staining test were undertaken to investigate the effects of Ganoderma lucidum(Leyss ex Fr) Karst Compound(GLC) on the proliferation and differentiation of K562 leukemic cells. The results showed that different concentrations of GLC(from 4 mg.ml-1 to 12 mg.ml-1) could promote human bone marrow granulocyte-macrophage colony forming unit (CFU-GM) proliferation, but suppressed the growth of K562 leukemic cell colonies, and IC50 was 9.2 mg.ml-1. The data from liquid culture demonstrated that GLC could suppress K562 cells proliferation in a dose-dependent(from 4 mg.ml-1 to 20 mg.ml-1) and time-dependent(from 1-5 days) manner. K562 cells could be induced to differentiate into more mature erythrocytic cells by 4 mg.ml-1 and 8 mg.ml-1 GLC. It is concluded that GLC may be a good medicine for leukemia therapy.